Business Wire

Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program

Share

Celmatix Inc. a biotechnology company focused on ovarian biology, today announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. The program, which was a product of Celmatix’s decade-long focus on identifying novel biomarkers and drug targets for women’s health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy. Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.

“Demographically speaking, menopause is a relatively new phenomenon and is the result of medical breakthroughs that allow women to now routinely outlive their ovarian function” remarked Dr. Piraye Yurttas Beim, Celmatix founder and CEO. “A century ago, the average life expectancy for women globally was under 50, so most women did not live long enough to experience menopause. Today, it is the single most significant accelerator of age-related conditions such as osteoporosis and heart disease in women. The risk for developing multiple of these chronic diseases by age 70 increases by 300% for women who experience premature loss of ovarian function and menopause. At Celmatix we are committed to helping women maximize their health by optimizing and extending ovarian function. Our team has worked for over a decade to uncover the molecular drivers of ovarian health and related conditions like infertility, polycystic ovary syndrome (PCOS), and endometriosis. Through this work, it became clear to us that Anti-Müllerian Hormone (AMH), the natural ligand of AMHR2, is a fundamental regulator of ovarian function, much like estrogen. Unlike estrogen, however, AMH cannot be purified from natural sources like urine or chemically synthesized, and previous attempts failed to generate recombinant AMH analogs with high specific activity or pharmacokinetic stability necessary for therapeutic applications.”

"One of the things that attracted me as a drug developer to Celmatix was the potential of the AMHR2 agonist program to address significant unmet needs in women's health” explained Dr. Stephen Palmer, Chief Scientific Officer of Celmatix. "It was clear to me that Celmatix’s AMHR2 agonist program is on track to be a 21st century breakthrough, equivalent to the development last century of the birth control pill and IVF drugs. Our lead indication is chemotherapy induced ovarian failure (CIOF), but we believe that an AMHR2 agonist may also have applications in a broad range of women’s health indications. Our results demonstrate that our lead AMH analog has the desired in vivo pharmacokinetic parameters and causes the desired cellular signaling events in traditional ovarian follicular assays and regression of the Müllerian ducts in ex vivo urogenital ridge culture systems. Demonstrating high specific activity in both our target tissue (the ovary) and in the most well-established assay for AMH function gives us confidence to progress this program forward closer to the clinic.”

This announcement closely follows Celmatix’s achievement of the third milestone in its five-year, multi-target alliance with Evotec in January. The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.

About Celmatix

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 agonist program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information, visit the company’s website at www.celmatix.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jasmine Newby
celmatix@mww.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Napster Outlines New Web3 Music Ecosystem29.6.2022 18:15:00 CEST | Press release

Napster Music Inc., the music streaming service, today announced the publication of its Litepaper V1 which outlines its plans to apply Web3 technology to its existing business and millions of users in order to improve how music makers, rights holders and fans can interact. A new entity, Napster Innovation Foundation, will be issuing $NAPSTER tokens using the Algorand blockchain protocol to streamline its existing platform functionality as well as open up new options for creating value around streaming music. "We’re entering the streaming-plus era of music, which is one of the few scaled business sectors where adoption of blockchain tech actually makes immediate sense for everyone,” said Emmy Lovell, Interim CEO of Napster. “People who make music, people who listen to it and those who own its IP all already depend heavily on technology. Web3 offers a chance to deepen, extend and improve the music ecosystem.” “Napster is a strong, self-sustaining business and an iconic brand,” said Matt

izzi Taps Verimatrix XTD and Streamkeeper to Protect Its Popular Media Apps, Endpoint29.6.2022 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that izzi , a mexican telecommunications firm that offers the country’s popular izzi tv and izzi go services, is set to build upon its existing use of Verimatrix content protection and anti-piracy solutions with the addition of Streamkeeper as well as Extended Threat Defense (XTD) technologies to protect many of their fast-growing iOS, Android and web streaming services plus its Android set-top box services. With an ever-increasing customer base with millions of users throughout Mexico and a vast array of premium entertainment delivery platforms, izzi decided to expand its use of Verimatrix following success with its current VCAS and Multi-DRM deployments. Verimatrix XTD will soon be used to protect code within all of the company’s PayTV apps throughout all izzi platforms, while the company will also benefit from comprehensive

EIG Launches Chilean Renewables Platform, Grupo Cerro29.6.2022 17:00:00 CEST | Press release

EIG, an institutional investor to the global energy sector and one of the world’s leading infrastructure investors, today launched Grupo Cerro, a new renewable energy platform in Chile. The newly formed entity includes EIG-owned Cerro Dominador plants and the recently acquired ANPAC, the owner of a portfolio of 11 small and medium run-of-river hydroelectric power plants in the O’Higgins, El Maule, Bio Bio and La Araucania regions. The 110 MW ANPAC portfolio includes operating plants and projects at various stages of construction and development in both the spot and stabilized-tariff markets. Following the acquisition, Grupo Cerro now manages over 280 MW of installed capacity in Chile, including the Cerro Dominador Photovoltaic (PV) and Concentrated Solar Power (CSP) plants. The group’s portfolio also includes several projects in advanced phases of construction and development, including the Likana Solar complex, one of the largest CSP projects in the world with a capacity of 690 MW, Pa

Trackforce Valiant Acquires TrackTik Software, Creates the World’s Largest Security Workforce Management Company29.6.2022 16:00:00 CEST | Press release

Trackforce Valiant, a leading provider of security workforce management solutions, today announced the acquisition of TrackTik Software, one of the most innovative and fastest growing cloud-based security workforce management providers. The combination of these two companies has created a new dominant market leader in providing visibility and control for the physical security workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005064/en/ “We are very excited to welcome TrackTik into the Trackforce Valiant family,” said Trevor Campion, CEO of Trackforce Valiant. “Now more than ever, we believe in the importance of providing the right security solutions for companies of all sizes and business needs. The addition of TrackTik enables us to provide a wide range of technology options that are purpose-built for the unique needs of physical security operations.” TrackTik was founded in 2013 with the mission of providing

Hy Stor Energy Strategic Partnership with Key Gulf Coast Port Becomes First to Deliver Renewable Hydrogen Access for Manufacturing, Industrial Applications, Port Operations and Long Duration Energy Storage29.6.2022 15:00:00 CEST | Press release

Hy Stor Energy LP (Hy Stor Energy), a company pioneering renewably produced green hydrogen and energy storage at scale in Mississippi, announced today a strategic partnership with the Hancock County Port and Harbor Commission (HCPHC) to provide zero-carbon, zero-methane hydrogen to Port Bienville Industrial Park and Stennis International Airport, accelerating the decarbonization of land, air, sea, and space. Through this partnership, Port Bienville will be the first port in the Gulf Region to integrate renewable hydrogen as a fuel into its operations. During the first phase of the partnership, the hydrogen hub is expected to produce an estimated 350 tons/day (320,000 kg/day) of renewable hydrogen and store more than 71,000 tons (69 million kg) of hydrogen in underground salt caverns. The existing Port Bienville infrastructure will expand to better enable decarbonization efforts and will be in a premium location to allow for new manufacturing of circular hydrogen infrastructure – the fi